Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone

被引：0
|
作者：
Mathews, Maju [1 ]
Pei, Huiling [1 ]
Savitz, Adam [1 ]
Nuamah, Isaac [1 ]
Elefant, Erica [1 ]
Hough, David [1 ]
Alphs, Larry [1 ]
Gopal, Srihari [1 ]
机构：
[1] Janssen Res & Dev, Titusville, NJ USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PM409
引用
收藏
页码：197 / 198
页数：2
相关论文
共 50 条
  • [31] Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
    Mathews, Maju
    Nuamah, Isaac
    Savitz, Adam J.
    Hough, David W.
    Najarian, Dean
    Kim, Edward
    Gopal, Srihari
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2018, 14 : 2807 - 2816
  • [32] Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia
    Wang, Grace Hsin-Min
    Svensson, Mikael
    Shao, Hui
    Vouri, Scott Martin
    Park, Haesuk
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (08): : 884 - 895
  • [33] Assessment of hospitalizations in schizophrenia patients treated with paliperidone 1-monthly (PP1M), paliperidone 3-monthly (PP3M), aripiprazole oncemonthly (AOM) and other oral antipsychotics (OAP) in clinical practice.
    Gutierrez Rojas, L.
    Sanchez Alonso, S.
    Garcia Dorado, M.
    Lopez, P.
    EUROPEAN PSYCHIATRY, 2021, 64 : S539 - S539
  • [34] A PRELIMINARY COST ANALYSIS OF SCHIZOPHRENIC PATIENTS STABILIZED ON 1-MONTHLY LONG ACTING PALIPERIDONE PALMITATE (PP1M) INJECTION SWITCHING TO PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION (PP3M) IN THE PUBLIC SECTOR OF HONG KONG
    Choon, W. Y.
    Wu, D. B.
    Lee, K. K.
    VALUE IN HEALTH, 2017, 20 (09) : A711 - A711
  • [35] Stable schizophrenia patients switched to paliperidone palmitate 3-monthly formulation in real life: impact on caregiver burden
    Maina, G.
    Garcia-Portilla, M. P.
    Llorca, P. M.
    Bozikas, V. P.
    Devrimci-Ozguven, H.
    Kim, S. W.
    Bergmans, P.
    Strulev, V.
    Cherubin, P.
    Pungor, K.
    EUROPEAN PSYCHIATRY, 2019, 56 : S262 - S262
  • [36] Stable schizophrenia patients switched to paliperidone palmitate 3-monthly formulation in real life: functioning and resource use
    Garcia-Portilla, P.
    Llorca, P. M.
    Maina, G.
    Bozikas, V. P.
    Devrimci-Ozguven, H.
    Kim, S. W.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    Pungor, K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S238 - S239
  • [37] Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
    Carpiniello, Bernardo
    Pinna, Federica
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1731 - 1742
  • [38] Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia
    Gopal, Srihari
    Vermeulen, An
    Nandy, Partha
    Ravenstijn, Paulien
    Nuamah, Isaac
    Vidal, Jose Antonio Buron
    Berwaerts, Joris
    Savitz, Adam
    Hough, David
    Samtani, Mahesh N.
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (11) : 2043 - 2054
  • [39] New Zealand community mental healthcare provider experience in schizophrenia management with 3-monthly paliperidone palmitate
    Cassidy, Cathal
    Miles, Wayne
    AUSTRALASIAN PSYCHIATRY, 2021, 29 (03) : 299 - 304
  • [40] Nurse education on the administration of Paliperidone Palmitate 3 monthly formulation for schizophrenia
    Nolan-Isles, Fran
    Bedson, Sue
    INTERNATIONAL JOURNAL OF MENTAL HEALTH NURSING, 2017, 26 : 32 - 33
12345